UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Cancer pain management: Interventional therapies

Authors
Ronald Kaplan, MD
Russell K Portenoy, MD
Section Editor
Janet Abrahm, MD
Deputy Editors
Diane MF Savarese, MD
Marianna Crowley, MD

INTRODUCTION

Chronic pain that is severe enough to warrant long-term opioid therapy is experienced by 30 to 50 percent of cancer patients undergoing active antineoplastic therapy and by 75 to 90 percent of those with advanced disease [1,2]. Treatment guidelines for cancer pain emphasize the primary role of systemic opioid therapy [3-5], which can yield adequate relief in 70 to 90 percent of patients [6]. This favorable statistic underscores the need to provide patients with access to opioid-based systemic pharmacotherapy for moderate to severe cancer pain. (See "Cancer pain management: General principles and risk management for patients receiving opioids" and "Cancer pain management with opioids: Optimizing analgesia".)

However, despite optimization of opioid therapy and the use of analgesic adjuvants, a substantial number of patients with cancer pain do not obtain satisfactory relief with first-line analgesic therapy. (See "Cancer pain management: Adjuvant analgesics (coanalgesics)" and "Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs".)

When effective pain relief cannot be achieved through pharmacologic means, nonpharmacologic approaches offer an important alternative. The most important of these nonpharmacologic approaches are the so-called “interventional” pain management strategies. Interventional strategies comprise a very diverse group of invasive therapies, most of which are nondestructive and performed using needles (table 1). Interventional therapies include injections, non-neurolytic and neurolytic nerve blocks, and implanted neurostimulation and neuraxial drug infusion techniques. The evidence base for all of these approaches is limited and includes very few controlled trials. Nevertheless, there is acceptance of these approaches in cancer pain management.

With the exception of some simple injections (eg, trigger point injections), interventional therapies for pain management are implemented by professionals who have received specialized training. Ideally, all patients with cancer pain that does not respond promptly to systemic pharmacotherapy should have access to a specialist who can assess the appropriateness of interventional treatments.

This topic review will cover interventional therapies for cancer pain. General principles of cancer pain assessment and management; the use of pharmacologic therapies for cancer pain, including opioids, analgesic adjuvants, acetaminophen and NSAIDs; and psychologic, rehabilitative, and integrative therapies are discussed elsewhere. (See appropriate topic reviews).

                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Aug 10 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007; 132:312.
  2. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34:94.
  3. WHO. Cancer Pain Relief, 2nd, World Health Organization, Geneva 1996.
  4. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 6th, American Pain Society, Glenview, IL, 2008.
  5. Fine, P, Portenoy, RK. Opiod analgesia, McGraw Hill, New York 2004.
  6. Quigley C. Opioids in people with cancer-related pain. BMJ Clin Evid 2008; 2008.
  7. Sist T, Miner M, Lema M. Characteristics of postradical neck pain syndrome: a report of 25 cases. J Pain Symptom Manage 1999; 18:95.
  8. Sist T, Wong C. Difficult problems and their solutions in patients with cancer pain of the head and neck areas. Curr Rev Pain 2000; 4:206.
  9. Chew C, Craig L, Edwards R, et al. Safety and efficacy of percutaneous vertebroplasty in malignancy: a systematic review. Clin Radiol 2011; 66:63.
  10. Bouza C, López-Cuadrado T, Cediel P, et al. Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis. BMC Palliat Care 2009; 8:12.
  11. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 2011; 12:225.
  12. Chwistek M, Mehta RS. Vertebroplasty and kyphoplasty for vertebral compression fractures #202. J Palliat Med 2012; 15:1151.
  13. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013; 31:2347.
  14. Bhargava A, Trivedi D, Kalva L, et al. Management of cancer-related vertebral compression fracture: Comparison of treatment options- A literature meta-analysis (abstract). J Clin Oncol 27, 2009 (suppl; abstr e20529) Abstract available online at http://meetinglibrary.asco.org/content/31125-65 (Accessed on August 30, 2013).
  15. Sabuncuoğlu H, Dinçer D, Güçlü B, et al. Intradural cement leakage: a rare complication of percutaneous vertebroplasty. Acta Neurochir (Wien) 2008; 150:811.
  16. Hulme PA, Krebs J, Ferguson SJ, Berlemann U. Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies. Spine (Phila Pa 1976) 2006; 31:1983.
  17. Taylor RS, Taylor RJ, Fritzell P. Balloon kyphoplasty and vertebroplasty for vertebral compression fractures: a comparative systematic review of efficacy and safety. Spine (Phila Pa 1976) 2006; 31:2747.
  18. Armingeat T, Brondino R, Pham T, et al. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006; 17:1659.
  19. Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999; 18:266.
  20. Abdulla AJ. Use of pamidronate for acute pain relief following osteoporotic vertebral fractures. Rheumatology (Oxford) 2000; 39:567.
  21. Hogan, Q, Abram, S. Diagnostic and prognostic neural blockade. In: Cousins and Bridenbaugh's Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th, Lippencott, Williams & Wilkins, 2009. p.839.
  22. Buckley, FP. Regional anesthesia with local anesthetics. In: Bonica's Management of Pain, 3rd, Lippincott, Williams & Wilkins, 2001. p.1893.
  23. Stein, C, Kopf, A. Regional anesthesia and treatment of chronic pain. In: Miller's Anesthesia, 7th, Churchill Livingstone Elsevier, 2010. p.1808.
  24. Straube S, Derry S, Moore RA, McQuay HJ. Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. Cochrane Database Syst Rev 2010; :CD002918.
  25. Pacenta HL, Kaddoum RN, Pereiras LA, et al. Continuous tunnelled femoral nerve block for palliative care of a patient with metastatic osteosarcoma. Anaesth Intensive Care 2010; 38:563.
  26. Fujii T, Nagaro T, Tsubota S, et al. Case reports: management of intractable upper extremity pain with continuous subarachnoid block at the low cervical level without impairment of upper extremity function. Anesth Analg 2010; 110:1721.
  27. Vranken JH, Zuurmond WW, de Lange JJ. Continuous brachial plexus block as treatment for the Pancoast syndrome. Clin J Pain 2000; 16:327.
  28. Chambers WA. Nerve blocks in palliative care. Br J Anaesth 2008; 101:95.
  29. Burton, AW, Phan, PC, Cousins, MJ. Treatment of cancer pain: Role of neural blockade and neuromodulation. In: Cousins and Bridenbaugh's Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th, Lippincott, Williams & Wilkins, 2009. p.1122.
  30. Lema, MJ. Invasive procedures for cancer pain. Pain: Clinical Updates; 6:1. International Association for the Study of Pain ( IASP) available online at http://www.iasp-pain.org/AM/AMTemplate.cfm?Section=Home&TEMPLATE=/CM/ContentDisplay.cfm&CONTENTID=7603.
  31. Rowe DS. Neurolytic techniques for pain management. Jacksonville Medicine; October 1998. http://www.dcmsonline.org/jax-medicine/1998journals/october98/neurolytic.htm (Accessed on March 28, 2011).
  32. Ganji, A. Cancer pain management. Biomedical Imaging and Intervention Journal 2007; 3(1):e12, accessed online at http://www.biij.org/2007/1/e12/abstract.asp?ID=230 (Accessed on August 30, 2010).
  33. Candido K, Stevens RA. Intrathecal neurolytic blocks for the relief of cancer pain. Best Pract Res Clin Anaesthesiol 2003; 17:407.
  34. Slatkin NE, Rhiner M. Phenol saddle blocks for intractable pain at end of life: report of four cases and literature review. Am J Hosp Palliat Care 2003; 20:62.
  35. Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; :CD007519.
  36. Amr YM, Makharita MY. Neurolytic sympathectomy in the management of cancer pain-time effect: a prospective, randomized multicenter study. J Pain Symptom Manage 2014; 48:944.
  37. Wyse JM, Carone M, Paquin SC, et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29:3541.
  38. Plancarte R, de Leon-Casasola OA, El-Helaly M, et al. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 1997; 22:562.
  39. de Leon-Casasola OA, Kent E, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain 1993; 54:145.
  40. Landau B, Levy RM. Neuromodulation techniques for medically refractory chronic pain. Annu Rev Med 1993; 44:279.
  41. Ferrante FM. Neuraxial infusion in the management of cancer pain. Oncology (Williston Park) 1999; 13:30.
  42. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040.
  43. Gildenberg, PL. History of electrical neuromodulation for chronic pain. Pain Medicine 2006; 7:S7. Available online at http://www.sld.cu/galerias/pdf/sitios/rehabilitacion-fis/history_of_electrical_neuromodulation_for_chronic_pain.pdf (Accessed on August 30, 2010).
  44. McCartney, CJL, Chambers, WA. Central neuraxial techniques for cancer pain. Curr Anaesth Crit Care 2000; 11:166.Available online at http://www.currentanaesthesia.com/article/S0953-7112(00)90268-0/abstract (Accessed on August 30, 2010).
  45. Peng L, Min S, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev 2015; :CD009389.
  46. Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the Neuromodulation Appropriateness Consensus Committee. Neuromodulation 2014; 17:515.
  47. Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol 2010; 8:52.
  48. Birthi P, Sloan P. Interventional treatment of refractory cancer pain. Cancer J 2013; 19:390.
  49. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference--2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012; 15:420.
  50. van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999; 15:166.
  51. Penning JP, Yaksh TL. Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat. Anesthesiology 1992; 77:1186.
  52. Dahl JB, Rosenberg J, Hansen BL, et al. Differential analgesic effects of low-dose epidural morphine and morphine-bupivacaine at rest and during mobilization after major abdominal surgery. Anesth Analg 1992; 74:362.
  53. Sjöberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 1994; 80:284.
  54. Do Ouro S, Esteban S, Sibirceva U, et al. Safety and tolerability of high doses of intrathecal fentanyl for the treatment of chronic pain. J Opioid Manag 2006; 2:365.
  55. Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995; 61:391.
  56. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003; 26:668.
  57. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012; 15:436.
  58. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy--a survey of clinical trends and decision making. J Pain Symptom Manage 2000; 20:S4.
  59. Brogan SE, Winter NB, Okifuji A. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. Reg Anesth Pain Med 2015; 40:369.
  60. Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005; 16:825.
  61. Hassenbusch SJ, Pillay PK, Magdinec M, et al. Constant infusion of morphine for intractable cancer pain using an implanted pump. J Neurosurg 1990; 73:405.
  62. Holmfred A, Vikerfors T, Berggren L, Gupta A. Intrathecal catheters with subcutaneous port systems in patients with severe cancer-related pain managed out of hospital: the risk of infection. J Pain Symptom Manage 2006; 31:568.
  63. Mercadante S, Intravaia G, Villari P, et al. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007; 23:793.
  64. Deer TR, Levy R, Prager J, et al. Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation 2012; 15:467.
  65. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation 2012; 15:483.
  66. Kurita GP, Kaasa S, Sjøgren P, European Palliative Care Research Collaborative (EPCRC). Spinal opioids in adult patients with cancer pain: a systematic review: a European Palliative Care Research Collaborative (EPCRC) opioid guidelines project. Palliat Med 2011; 25:560.
  67. Dennis GC, DeWitty RL. Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 1990; 26:404.